TrialGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2024

Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial.

Yoon-Koo Kang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.